journal article·2022-01-21Open access

Safety Profile of Rapamycin Perfluorocarbon Nanoparticles for Preventing Cisplatin-Induced Kidney Injury

Qingyu Zhou, Justin Doherty, Antonina Akk, Luke E. Springer, Ping Fan, Ivan Spasojevic, Ganesh V. Halade, Huanghe Yang, Christine T. N. Pham, Samuel A. Wickline, Hua Pan

Nanomaterials· Volume 12· Issue 3

Abstract

Cancer treatment-induced toxicities may restrict maximal effective dosing for treatment and cancer survivors’ quality of life. It is critical to develop novel strategies that mitigate treatment-induced toxicity without affecting the efficacy of anti-cancer therapies. Rapamycin is a macrolide with anti-cancer properties, but its clinical application has been hindered, partly by unfavorable bioavailability, pharmacokinetics, and side effects. As a result, significant efforts have been undertaken to develop a variety of nano-delivery systems for the effective and safe administration of rapamycin. While the efficacy of nanostructures carrying rapamycin has been studied intensively, the pharmacokinetics, biodistribution, and safety remain to be investigated. In this study, we demonstrate the potential for rapamycin perfluorocarbon (PFC) nanoparticles to mitigate cisplatin-induced acute kidney injury with a single preventative dose. Evaluations of pharmacokinetics and biodistribution suggest that the PFC nanoparticle delivery system improves rapamycin pharmacokinetics. The safety of rapamycin PFC nanoparticles was shown both in vitro and in vivo. After a single dose, no disturbance was observed in blood tests or cardiac functional evaluations. Repeated dosing of rapamycin PFC nanoparticles did not affect overall spleen T cell proliferation and responses to stimulation, although it significantly decreased the number of Foxp3+CD4+ T cells and NK1.1+ cells were observed.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Chemotherapy-induced organ toxicity mitigation · Childhood Cancer Survivors' Quality of Life · Acute Lymphoblastic Leukemia research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutical Sciences, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33612, USA

USF Health Heart Institute, University of South Florida, Tampa, FL 33602, USA

Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA

School of Medicine, Duke University, Durham, NC 27708, USA

John Cochran Veterans Affairs Medical Center, St. Louis, MO 63106, USA

Altamira Therapeutics Inc., Dover, DE 19901, USA

Funding

National Institutes of Health

References (68)

Show source-provided references
1. Cancer treatment and survivorship statistics, 201610.3322/caac.21349 ↗
2. NCI (2019). Cancer Statistics, NCI.
3. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy10.1001/jama.290.21.2831 ↗
4. Chronic health conditions in adult survivors of childhood cancer10.1056/NEJMsa060185 ↗
5. The cardiovascular perils of cancer survivorship10.1056/NEJMe1215300 ↗
6. Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology10.6004/jnccn.2018.0078 ↗
7. Cardiotoxicity: Cisplatin and long-term cancer survivors10.1016/j.ijcard.2014.04.238 ↗
8. The impact of cumulative dose of cisplatin on outcome of patients with head and neck squamous cell carcinoma10.1007/s00405-017-4687-4 ↗
9. Anthracycline cardiotoxicity: An update on mechanisms, monitoring and prevention10.1136/heartjnl-2017-312103 ↗
10. Inhibition of Cell Division in Escherichia Coli by Electrolysis Products from a Platinum Electrode10.1038/205698a0 ↗
11. NCI (2014). The “Accidental” Cure—Platinum-Based Treatment for Cancer: The Discovery of Cisplatin, NCI.
13. Comparative nephrotoxicity of platinum cancer chemotherapeutic agents
14. The renal pathology in clinical trials of cis-platinum (II) diamminedichloride10.1002/1097-0142(197704)39:4<1362::AID-CNCR2820390403>3.0.CO;2-N ↗
15. Clinical development of platinum complexes in cancer therapy: An historical perspective and an update10.1016/S0959-8049(98)00224-X ↗
16. Clinical trials of cis-diamminedichloroplatinum (NSC-119875)
17. Acute kidney injury and chronic kidney disease as interconnected syndromes10.1056/NEJMra1214243 ↗
18. Long-term risk of coronary events after AKI10.1681/ASN.2013060610 ↗
19. Increased risk of death and de novo chronic kidney disease following reversible acute kidney injury10.1038/ki.2011.405 ↗
20. Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: Relevance of age and dose as risk factors10.1016/j.ejca.2009.06.032 ↗
21. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization10.7164/antibiotics.28.727 ↗
22. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle10.7164/antibiotics.28.721 ↗
23. Sourcing a chemical succession for cyclosporin from parasites and human pathogens10.1016/S1359-6446(05)03395-7 ↗
24. mTOR: A pharmacologic target for autophagy regulation10.1172/JCI73939 ↗
25. Rapamycin-induced autophagy plays a pro-survival role by enhancing up-regulation of intracellular ferritin expression in acute lymphoblastic leukemia10.32471/exp-oncology.2312-8852.vol-42-no-1.14067 ↗
26. Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies10.1038/cdd.2008.110 ↗
27. Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK10.1101/gad.1662308 ↗
28. NF-kappaB transcriptional inhibition ameliorates cisplatin-induced acute kidney injury (AKI)10.1016/j.toxlet.2015.10.028 ↗
29. Penicilliumin B Protects against Cisplatin-Induced Renal Tubular Cell Apoptosis through Activation of AMPK-Induced Autophagy and Mitochondrial Biogenesis10.1159/000514657 ↗
30. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase10.1038/358070a0 ↗
31. Poly(ethylene glycol)-block-poly(2-methyl-2-benzoxycarbonyl-propylene carbonate) micelles for rapamycin delivery: In vitro characterization and biodistribution10.1002/jps.22467 ↗
32. Pharmacometrics and delivery of novel nanoformulated PEG-b-poly(epsilon-caprolactone) micelles of rapamycin10.1007/s00280-007-0458-z ↗
33. Trilayer micelles for combination delivery of rapamycin and siRNA targeting Y-box binding protein-1 (siYB-1)10.1016/j.biomaterials.2013.05.010 ↗
34. Effective attenuation of vascular restenosis following local delivery of chitosan decorated sirolimus liposomes10.1016/j.carbpol.2016.11.021 ↗
35. Use of remote film loading methodology to entrap sirolimus into liposomes: Preparation, characterization and in vivo efficacy for treatment of restenosis10.1016/j.ijpharm.2011.04.055 ↗
36. Cholesterol-poly(ethylene) glycol nanocarriers for the transscleral delivery of sirolimus10.1016/j.exer.2014.02.001 ↗
37. Intramural delivery of rapamycin with alphavbeta3-targeted paramagnetic nanoparticles inhibits stenosis after balloon injury10.1161/ATVBAHA.107.156281 ↗
38. Rapamycin nanoparticles target defective autophagy in muscular dystrophy to enhance both strength and cardiac function10.1096/fj.13-237388 ↗
39. Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis10.1161/01.ATV.0000235724.11299.76 ↗
40. Heart functional and structural compendium of cardiosplenic and cardiorenal networks in acute and chronic heart failure pathology10.1152/ajpheart.00528.2017 ↗
41. Emerging nanomedicine opportunities with perfluorocarbon nanoparticles10.1586/17434440.4.2.137 ↗
42. Danaei, M., Dehghankhold, M., Ataei, S., Hasanzadeh Davarani, F., Javanmard, R., Dokhani, A., Khorasani, S., and Mozafari, M.R. (2018). Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems. Pharmaceutics, 10.10.3390/pharmaceutics10020057 ↗
43. Sustained local inhibition of thrombin preserves renal microarchitecture and function after onset of acute kidney injury10.1016/j.nano.2021.102449 ↗
44. Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients10.2165/00003088-200645110-00007 ↗
45. Nonlinear population pharmacokinetics of sirolimus in patients with advanced cancer10.1038/psp.2012.18 ↗
46. Optimization and Pharmacokinetic Evaluation of Synergistic Fenbendazole and Rapamycin Co-Encapsulated in Methoxy Poly(Ethylene Glycol)-b-Poly(Caprolactone) Polymeric Micelles10.2147/IJN.S315782 ↗
47. Population pharmacokinetics of sirolimus in kidney transplant patients10.1016/S0009-9236(97)90192-2 ↗
48. Development of a Physiologically-Based Pharmacokinetic Model for Sirolimus: Predicting Bioavailability Based on Intestinal CYP3A Content10.1038/psp.2013.33 ↗
49. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration10.1002/j.1552-4604.1997.tb04318.x ↗
50. A randomized, double-blind, placebo-controlled study to determine safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients
51. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus10.1016/S0149-2918(00)89027-X ↗
52. Rapamycin: Distribution, pharmacokinetics and therapeutic range investigations: An update10.1016/S0009-9120(98)00048-4 ↗
53. A novel rapamycin analog is highly selective for mTORC1 in vivo10.1038/s41467-019-11174-0 ↗
54. Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system10.1111/acel.12405 ↗
55. Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers10.1067/mcp.2001.112513 ↗
56. Cisplatin-induced cardiotoxicity with midrange ejection fraction: A case report and review of the literature10.1097/MD.0000000000013807 ↗
57. Cisplatin induced paroxysmal supraventricular tachycardia10.4103/0971-5851.125262 ↗
58. Comprehensive Characterization of the Vascular Effects of Cisplatin-Based Chemotherapy in Patients with Testicular Cancer10.1016/j.jaccao.2020.06.004 ↗
59. Cardiovascular risk in long-term survivors of testicular cancer10.1002/cncr.23389 ↗
60. The cardiac impact of cisplatin-based chemotherapy in survivors of testicular cancer: A 30-year follow-up10.1093/ehjci/jeaa289 ↗
61. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload10.1161/01.CIR.0000130641.08705.45 ↗
62. Rapamycin regulates the balance between cardiomyocyte apoptosis and autophagy in chronic heart failure by inhibiting mTOR signaling
63. Rapamycin persistently improves cardiac function in aged, male and female mice, even following cessation of treatment10.1111/acel.13086 ↗
64. Rapamycin Inhibits Cardiac Hypertrophy by Promoting Autophagy via the MEK/ERK/Beclin-1 Pathway10.3389/fphys.2016.00104 ↗
65. Rel/NF-kappaB family member RelA regulates NK1.1− to NK1.1+ transition as well as IL-15-induced expansion of NKT cells10.1002/eji.200737830 ↗
66. Induction of Foxp3 and activation of Tregs by HSP gp96 for treatment of autoimmune diseases10.1016/j.isci.2021.103445 ↗
67. FOXP3 and its role in the immune system10.1007/978-1-4419-1599-3_2 ↗
68. Selective transcription in response to an inflammatory stimulus10.1016/j.cell.2010.01.037 ↗